Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:27:29.637Z.
Calculation as of: 2026-10-06T18:27:29.637Z.
Quote observation: 2026-10-06T18:24:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9bf447c1d5373d17b51517f64cfe8ce44e33b4ae98b3907fdc05662a19d62e0e
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $39.15M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.81M | N/A | 328.93 | 271.56 | 151.89 |
| Incannex Healthcare Limited (IXHL)vs › | $37.57M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $36.91M | 21.42 | 36.35 | 61.12 | 61.12 |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.39M | N/A | N/A | N/A | N/A |
| Veru Inc. (VERU)vs › | $41.30M | N/A | 243.89 | 230.07 | 202.94 |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.42M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A | N/A | N/A | N/A |
| Precipio, Inc. (PRPO)vs › | $42.15M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.04
Forward EPS (Est.)
$-2.49
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
